Dexcom (DXCM) Operating Expenses (2010 - 2026)

Dexcom (DXCM) has 17 years of Operating Expenses data on file, last reported at $495.0 million in Q1 2026.

• On a quarterly basis, Operating Expenses rose 8.72% year-over-year to $495.0 million in Q1 2026; TTM through Mar 2026 was $1.9 billion, a 5.3% increase from a year earlier, with the FY2025 full-year figure at $1.9 billion, up 2.82% from the prior year.
• Operating Expenses for Q1 2026 stood at $495.0 million, up from $469.7 million in the prior quarter.
• Over the last five years, Operating Expenses for DXCM reached as high as $495.0 million in Q1 2026 and fell as low as $346.7 million in Q3 2022.
• Historically, Operating Expenses has averaged $435.7 million across 5 years, with a median of $441.8 million in 2024.
• Across the five-year window, Operating Expenses fell 11.89% in 2022 and gained 20.51% in 2023, its largest moves.
• Year by year, Operating Expenses stood at $415.9 million in 2022, then grew by 5.72% to $439.7 million in 2023, then increased by 6.19% to $466.9 million in 2024, then climbed by 0.6% to $469.7 million in 2025, then rose by 5.39% to $495.0 million in 2026.
• Per Business Quant data, the three most recent Operating Expenses figures were $495.0 million in Q1 2026, $469.7 million in Q4 2025, and $488.9 million in Q3 2025.